Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Environ Monit Assess ; 190(4): 256, 2018 Mar 29.
Article in English | MEDLINE | ID: mdl-29594752

ABSTRACT

We investigated the depth profiles of radioactive Cs, ignition loss, and cation exchange capacity (CEC) in five types of forest soils sampled using scraper plates. We then simulated the monitored depth profiles in a compartment model, taking ignition loss as a parameter based on experimental results showing a positive correlation between ignition loss and the CEC. The calculated values were comparable with the monitored values, though some discrepancy was observed in the middle of the soil layer. Based on decontamination data on the surface dose rate and surface contamination concentration, we newly defined a surface residual index (SRI) to evaluate the residual radioactive Cs on surfaces. The SRI value tended to gradually decrease in forests and unpaved roads and was much smaller in forests and on unpaved roads than on paved roads. The radioactive Cs was assumed to have already infiltrated underground 18 months after the nuclear power plant accident, and the sinking was assumed to be ongoing. The SRI values measured on paved roads suggested that radioactive Cs remained on the surfaces, though a gradual infiltration was observed towards the end of the monitoring term. The SRI value is thought to be effective in grasping the rough condition of residual radioactive Cs quickly at sites of decontamination activity in the field. The SRI value may be serviceable for actual contamination works after further research is done to elucidate points such as the relation between the SRI and the infiltration of radioactive Cs in various types of objects.


Subject(s)
Cesium Radioisotopes/analysis , Forests , Radiation Monitoring , Soil Pollutants, Radioactive/analysis , Decontamination , Radioactive Hazard Release , Radioactivity , Soil
2.
Am J Physiol Heart Circ Physiol ; 295(3): H1279-H1287, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18660453

ABSTRACT

Aldosterone (Aldo) is recognized as an important risk factor for cardiovascular diseases. IL-18 induces myocardial hypertrophy, loss of contractility of cardiomyocytes, and apoptosis leading myocardial dysfunction. However, so far, there have been few reports concerning the interaction between Aldo and IL-18. The present study examined the effects and mechanisms of Aldo on IL-18 expression and the roles of peroxisome proliferator-activated receptor (PPAR) agonists in rat cardiomyocytes. We used cultured rat neonatal cardiomyocytes stimulated with Aldo to measure IL-18 mRNA and protein expression, Rho-kinase, and NF-kappaB activity. We also investigated the effects of PPAR agonists on these actions. Aldo, endothelin-1 (ET-1), and angiotensin II (ANG II) increased IL-18 mRNA and protein expression. Mineralocorticoid receptor antagonists, endothelin A receptor antagonist, and ANG II receptor antagonist inhibited Aldo-induced IL-18 expression. Aldo induced ET-1 and ANG II production in cultured media. Moreover, Rho/Rho-kinase inhibitor and statin inhibited Aldo-induced IL-18 expression. On the other hand, Aldo upregulated the activities of Rho-kinase and NF-kappaB. PPAR agonists attenuated the Aldo-induced IL-18 expression and NF-kappaB activity but not the Rho-kinase activity. Our findings indicate that Aldo induces IL-18 expression through a mechanism that involves, at a minimum, ET-1 and ANG II acting via the Rho/Rho-kinase and PPAR/NF-kappaB pathway. The induction of IL-18 in cardiomyocytes by Aldo, ET-1, and ANG II might, therefore, cause a deterioration of the cardiac function in an autocrine and paracrine fashion. The inhibition of the IL-18 expression by PPAR agonists might be one of the mechanisms whereby the beneficial cardiovascular effects are exerted.


Subject(s)
Aldosterone/pharmacology , Angiotensin II/physiology , Endothelin-1/physiology , Interleukin-18/biosynthesis , Myocytes, Cardiac/metabolism , Peroxisome Proliferator-Activated Receptors/physiology , rho-Associated Kinases/physiology , Animals , Animals, Newborn , Bezafibrate/pharmacology , Cells, Cultured , DNA Primers , Dose-Response Relationship, Drug , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/enzymology , NF-kappa B/drug effects , Oligopeptides/pharmacology , Peptides, Cyclic/pharmacology , Peroxisome Proliferator-Activated Receptors/agonists , Pioglitazone , Piperidines/pharmacology , Rats , Rats, Sprague-Dawley , Thiazolidinediones/pharmacology
3.
Hypertens Res ; 29(3): 187-95, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16755154

ABSTRACT

In hypertension, endothelium-dependent relaxation is attenuated and this attenuation contributes to the increased peripheral resistance. However, the role of endothelium-derived hyperpolarizing factor (EDHF) in the arteries of hypertensive rats remains unclear. Therefore, the aim of this study was to evaluate the role of EDHF in the femoral resistance arteries of hypertensive rats. The femoral resistance arteries were isolated from 5-, 15- and 25-week-old spontaneously hypertensive rats (SHR) and age-matched Wistar Kyoto rats (WKY). Changes in internal diameter were examined with videomicroscopy. EDHF-mediated dilatation was determined by differences between the degree of acetylcholine (ACh)-induced dilatation in the presence of NG-monomethy-L-arginine (L-NMMA) plus a prostaglandin I2 inhibitor (indomethacin) and the degree of such dilatation in the presence of L-NMMA, indomethacin and KCl. Charybdotoxin (CTx) and apamin (a Ca2+-activated K+ channel [KCa] inhibitor)-sensitive EDHF dilatation was also compared between in 5-, 15- and 25-week-old SHR and WKY. ACh-induced vasodilatation was not different between 5-week-old SHR and WKY. There was no difference between NO- and EDHF-mediated vasodilatation in 5-week-old rats. ACh-induced vasodilatation was weaker in 15-week-old SHR than in WKY. NO-mediated vasodilatation did not differ between the two groups. EDHF-mediated dilatation was attenuated in SHR but not in WKY. ACh-induced dilatation was weaker in 25-week-old SHR than in WKY. NO- and EDHF-mediated vasodilatation were attenuated in SHR but not WKY. EDHF-mediated vasodilatation was attenuated before the loss of NO-mediated vasodilatation in the femoral resistance arteries of SHR. The attenuation of this vasodilatation was mediated by the CTx plus apamin-sensitive EDHF.


Subject(s)
Arterioles/physiopathology , Biological Factors/physiology , Endothelium, Vascular/physiopathology , Hypertension/physiopathology , Nitric Oxide/physiology , Acetylcholine/pharmacology , Animals , Arterioles/drug effects , Endothelium, Vascular/drug effects , Femoral Artery/drug effects , Femoral Artery/physiopathology , Rats , Rats, Inbred SHR , Rats, Inbred WKY , Vasodilation/drug effects , Vasodilator Agents/pharmacology
4.
Clin Exp Pharmacol Physiol ; 33(1-2): 47-52, 2006.
Article in English | MEDLINE | ID: mdl-16445698

ABSTRACT

1. Alterations in a(1)-adrenoceptor signalling that result in enhanced contraction in resistance arteries in heart failure are not well characterized. To clarify whether this enhanced constriction is due to Ca(2+)-dependent or -independent effects, we measured the phenylephrine-induced changes in [Ca(2+)](i) in the presence of a Rho kinase inhibitor or an inositol 1,4,5-trisphosphate (IP(3)) receptor inhibitor. 2. Heart failure was induced in rats by ligation of the left coronary artery. Changes in the internal diameter of pressurized small femoral arteries were examined using videomicroscopy. Phenylephrine concentration-response curves, constructed in the presence of the Rho kinase inhibitor Y27632 (0.3 micromol/L) or the IP(3) receptor inhibitor xestospongin C (0.3 micromol/L), were compared in heart failure rats and sham-operated (control) rats; fura-2 Ca(2+) signals were measured in the arteries of both groups. 3. The heart : bodyweight ratio, lung : bodyweight ratio, left ventricular end-diastolic pressure and plasma B-type natriuretic peptide were significantly higher in heart failure rats compared with control rats. Phenylephrine-induced contractile responses and increases in [Ca(2+)](i) were significantly greater in arteries from heart failure rats compared with arteries from control rats. At 0.3 micromol/L, Y27632 selectively inhibited phenylephrine-induced constrictions of heart failure arteries, but had no effect on the increase in [Ca(2+)](i). 4. Immunohistochemical staining for Rho kinase was greater in heart failure rats compared with control rats. 5. The degree of inhibition of both the phenylephrine-induced constriction and the increase in [Ca(2+)](i) by xestospongin C (0.3 micromol/L) was greater in arteries from heart failure rats than in those from control rats. 6. The increased contractile response to phenylephrine in arteries of heart failure rats results from IP(3)-dependent increases in [Ca(2+)](i) and from an enhanced Ca(2+) sensitivity via a Rho kinase-dependent mechanism.


Subject(s)
Arteries/physiopathology , Heart Diseases/physiopathology , Receptors, Adrenergic, alpha/physiology , Vasoconstriction/physiology , Adrenergic alpha-Agonists/pharmacology , Amides/pharmacology , Animals , Arteries/drug effects , Arteries/metabolism , Calcium/metabolism , Dose-Response Relationship, Drug , Heart Diseases/metabolism , Immunohistochemistry , In Vitro Techniques , Intracellular Signaling Peptides and Proteins , Macrocyclic Compounds , Male , Muscle Relaxants, Central/pharmacology , Nitrendipine/pharmacology , Oxazoles/pharmacology , Phenylephrine/pharmacology , Protein Serine-Threonine Kinases/metabolism , Pyridines/pharmacology , Rats , Rats, Wistar , Vascular Resistance , Vasoconstriction/drug effects , Vasodilator Agents/pharmacology , rho-Associated Kinases
5.
Toxicol Sci ; 80(1): 161-9, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15056799

ABSTRACT

Indirubin is a natural arylhydrocarbon receptor (AhR) ligand isolated from human urine. We previously reported that it was more potent than the prototypical ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in a yeast assay system. Here we compared gene expression changes in HepG2 cells exposed to 10 nM of indirubin or TCDD using nylon-membrane-based cDNA arrays with 1176 genes to elucidate the toxic differences at the transcriptional level. The gene expression profiles for TCDD and indirubin were very similar. The number of up-regulated genes (fold change > or =2.0) was 11 and 4 and the number of down-regulated genes (fold change < or =0.5) was 17 and 21 in TCDD-treated and indirubin-treated cells, respectively. Cytochrome P450 (CYP) 1A1, 1A2, 19A1, insulin-like growth factor binding protein 1 (IGFBP1), and IGFBP10 were confirmed to be up-regulated using real-time reverse transcription polymerase chain reaction. CYP1A1 and CYP1A2 mRNAs were induced by as little as 1 pM of indirubin, whereas they were not induced by 10 pM of TCDD. In the time-course experiment, CYP1A1 mRNA was induced by indirubin transiently. Indirubin was also metabolized by CYP1A1 and lost its ligand activity. Indirubin would appear to be a good substrate of CYP1A1 given its low dissociation constant. Our results suggest that indirubin rapidly activates its own metabolism via AhR-mediated induction of CYP1A1 and this characteristic is consistent with the notion that indirubin is a physiological ligand of AhR.


Subject(s)
Gene Expression Profiling , Gene Expression/drug effects , Indoles/metabolism , Polychlorinated Dibenzodioxins/metabolism , Receptors, Aryl Hydrocarbon/metabolism , Animals , Cell Line, Tumor , Cytochrome P-450 Enzyme System/metabolism , Dose-Response Relationship, Drug , Humans , In Vitro Techniques , Indoles/toxicity , Insecta , Ligands , Microsomes/metabolism , Polychlorinated Dibenzodioxins/toxicity , Reverse Transcriptase Polymerase Chain Reaction , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...